ANI Pharmaceuticals Posts Strong Q2 2026 Growth on Cortrophin Gel Momentum — ANI Pharmaceuticals, Inc.

Event summary

Q2 2026 net revenues up 25.9% YoY to $266.0M, driven by Cortrophin Gel's 43.5% growth.
Cortrophin Gel sales reached $117.1M, with expansion into gout treatment showing early success.
Adjusted non-GAAP EBITDA increased 32.4% YoY to $71.6M.
Company reaffirmed full-year revenue guidance of $1.08B–$1.14B and adjusted EBITDA of $285M–$300M.
Share repurchase program authorized for up to $100M through May 2029.

The big picture

ANI Pharmaceuticals' strong Q2 2026 results highlight its strategic focus on Rare Disease products, particularly Cortrophin Gel. The company's expansion into new therapeutic areas like gout underscores its commitment to diversifying revenue streams. In a competitive biopharmaceutical landscape, ANI's ability to balance growth with financial discipline will be critical for maintaining investor confidence.

What we're watching

Product Expansion: The success of Cortrophin Gel's expansion into gout treatment will determine its long-term growth trajectory.
Financial Discipline: Whether ANI can sustain high margins while investing in sales force expansion and R&D.
Regulatory Dynamics: The impact of potential regulatory changes on the company's product pipeline and market positioning.